SPOTLIGHT -
EP. 1: Considerations for Biopsy in Diagnosing HCC
EP. 2: Noninvasive Methods for the Diagnosis of HCC
EP. 3: HCC Staging Systems Explored
EP. 4: Recognizing HCC Risk Factors
EP. 5: Challenges in Managing Newly Diagnosed Advanced HCC
EP. 6: Locoregional Therapies for Advanced HCC
EP. 7: Locoregional Versus Systemic Therapy for HCC
EP. 8: Liver-Directed Therapy +/- Sorafenib in HCC
EP. 9: Upfront Lenvatinib in Unresectable HCC
EP. 10: Practical Considerations for Using Lenvatinib in HCC
EP. 11: Appropriateness for Regorafenib in Metastatic HCC
EP. 12: Immunotherapy in Second-Line Metastatic HCC
EP. 13: Checkpoint Inhibitors Versus TKI Therapy in HCC
EP. 14: Multitargeted TKI Therapy in Metastatic HCC
EP. 15: Anti-VEGF Therapy in Metastatic HCC
EP. 16: Perspectives on the Future Treatment of HCC
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
